Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease

PHASE4TerminatedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions
Parkinson's Disease
Interventions
DRUG

Rivastigmine

Capsule. Dose 3,0 - 6,0 mg BID

DRUG

Placebo (for rivastigmine)

Capsule. Dose 3,0 - 6,0 mg BID

Trial Locations (4)

1100 DD

Academic Medical Center, Amsterdam

9700 RB

University Medical Center Groningen, Groningen

6401 CX

Atrium Medical Center, Heerlen

6500 HB

University Medical Center St Radboud, Nijmegen

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

collaborator

Atrium Medical Center

OTHER

collaborator

University Medical Center Groningen

OTHER

collaborator

Leiden University Medical Center

OTHER

collaborator

University Medical Center Nijmegen

OTHER

collaborator

International Parkinson Fonds Germany GmbH

INDUSTRY

collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

lead

Amsterdam UMC, location VUmc

OTHER

NCT01856738 - Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease | Biotech Hunter | Biotech Hunter